The first whole slide imaging (WSI) system that allows for review and interpretation of digital prostate cancer pathology slides prepared from biopsied tissue has been approved by the U.S. Food and Drug Administration (FDA).
Malecare is a leading advocate of second and third opinions of prostate cancer pathology from biopsy samples. The logistics of shipping and tracking glass slides of tissue inhibits men seeking multiple opinions.
The Philips IntelliSite Pathology Solution (PIPS) allows pathologists to read tissue slides digitally in order to make diagnoses, rather than looking directly at a tissue sample mounted on a glass slide under a conventional light microscope,” said Alberto Gutierrez, PhD, director of the office of in vitro diagnostics and radiological health in the FDA’s Center for Devices and Radiological Health.”
“Because the system digitizes slides that would otherwise be stored in physical files, it also provides a streamlined slide storage and retrieval system that may ultimately help make critical health information available to pathologists, other health care professionals and patients faster.”
This is a huge step forward in developing greater accuracy and insight around initial prostate cancer diagnosis and disease progression for advanced stage prostate cancer men seeking second biopsies.